lymphokine-activated killer cells children advanced metastatic neuroblastoma phase II trial lymphokine-activated killer LAK cells attempt children end-stage neuroblastoma Fifteen patients median age years study Twelve relapse massive chemotherapy autologous bone marrow transplantation ABMT primary refractory disease conventional chemotherapy continuous infusion course double treatment period break Cytapheresis LAK progenitor cells rest period vitro culture LAK cells second cycle therapy phenotypic functional analysis immunologic parameters therapeutic protocol Toxicity significant toxic deaths cardiotoxicity respiratory distress reinfusion large amounts LAK cells case severe toxicity patient status ie heavy pretreatment significant clinical response immunologic monitoring phenotypic functional modifications patients initiation treatment unexpected absence evolution parameters therapy origin immune dysfunctions clear failure therapy Future studies therapy neuroblastoma course disease 